Search results
Results from the WOW.Com Content Network
Diagnosis of geographic atrophy is made by an ophthalmologist in the clinic. Fundus autofluorescence and optical coherence tomography angiography are imaging modalities that can be used in the diagnosis. While fundus autofluorescence is the standard modality for viewing geographic atrophy, optical coherence tomography can offer unique benefits.
In advanced stages of AMD, atrophy of the RPE (geographic atrophy) and/or development of new blood vessels (neovascularization) result in the death of photoreceptors and central vision loss. [citation needed] In the dry (nonexudative) form, drusen accumulates between the retina and the choroid, causing atrophy and scarring to the retina. In the ...
Topographical disorientation is the inability to orient oneself in one's surroundings, sometimes as a result of focal brain damage. [1] This disability may result from the inability to make use of selective spatial information (e.g., environmental landmarks) or to orient by means of specific cognitive strategies such as the ability to form a mental representation of the environment, also known ...
As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, treatment and risk management that have been made in 2024. 5 major ...
Researchers at the University of Colorado Anschutz Medical Campus received up to $46 million in a grant to help develop an innovative treatment to cure blindness.
Lampalizumab is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
Pegcetacoplan is indicated to treat adults with paroxysmal nocturnal hemoglobinuria. [8] [9] [11] In February 2023, the indication was updated to include the treatment of people with geographic atrophy secondary to age-related macular degeneration.
(Reuters) - Iran, bracing for a possible re-imposition of incoming U.S. president Donald Trump's "maximum pressure" policy, said on Saturday that 2025 would be an important year for its nuclear issue.